A Fast and Simple, Non-Radioactive Assay to

A Fast and Simple, Non-Radioactive Assay to Replace EMSA in the
Monitoring of DNA-Protein Interactions
Julie Bédard1, Mathieu Larivière2, Daniel Sinnett2,3, Gregory Cosentino1 & Nathalie Rouleau1
Biotin-TEG-ATTCGATCGGGGCGGGGCGAG
Sp1 Mutated
ATTCGATCGGTTCGGGGCGAG
Biotin-Sp1 Mutated
Biotin-TEG-ATTCGATCGGTTCGGGGCGAG
HNF1 Consensus
TATTATGGTGAGCTAATAAGTTGCAAGTCCCT
Biotin-HNF1 Consensus
Biotin-TEG-TATTATGGTGAGCTAATAAGTTGCAAGTCCCT
HNF1 Mutated
TATTATGGTGAGCCAATAAGTTGCAAGTCCCT
Biotin-HNF1 Mutated
Biotin-TEG-TATTATGGTGAGCCAATAAGTTGCAAGTCCCT
Non-Specific Competitor
GATCGAACTGACCGCTTGCGGCCCGT
B
HNF1
400,000
Consensus
Mutated
350,000
300,000
250,000
200,000
150,000
100,000
50,000
0
-9
-8
5,000
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Add 5 µL Assay Buffer (Standard Assay
buffer was used for HNF1 experiments.
For Sp1 studies, the standard buffer
was supplemented with 3 µM ZnSO4)
Add 5 µL Hep G2 Nuclear Extracts
Add 5 µL biotinylated Oligos
Incubate for 30 (Sp1) or 60 (HNF1)
minutes at RT
Add 5 µL of a pre-mix composed of the
Ab with Protein A AlphaLISA® beads
(20 µg/mL) for Sp1 or the Ab with
Protein G AlphaLISA® beads (10
µg/mL) for HNF1
Incubate for 30 (Sp1) or 60 (HNF1)
minutes at RT
Add 5 µL SA-Donor beads (20 µg/mL
for Sp1 or 40 µg/mL for HNF1)
Incubate for 60 minutes at 23oC in the
dark
Read plate using an Alpha reader
60
180 200
120
700
Consensus
Mutated
5,000
2,500
0
1200
A
2,000
1,000
0
-∞
-10
-9
-8
-7
log [Biotinylated Oligos] (M)
B
Sp1
S/B= 70.4
350,000
Consensus
Mutated
300,000
250,000
200,000
150,000
100,000
50,000
0
-∞ -10
-9
-8
log [Ab] (M)
-7
S/B= 6.4
6,000
Consensus
Mutated
5,000
4,000
3,000
2,000
1,000
0
-11
-10
-9
700
1200
Detection incubation time (min)
Consensus
Mutated
400,000
S/B= 50.4
300,000
200,000
S/B 12.1
100,000
0
-7
-6
Consensus
Mutated
8,000
7,000
4,000
3,000
2,000
0
-7
-6
-5
Assay Variability
300,000
250,000
X = 217185
200,000
CV = 7 %
z'= 0,76
100,000
X = 7721
2
4
6
8
10
12
14
16
18
20
22
24
CV = 8 %
Well number
log [Ab] (M)
B
Consensus
Mutated
1,400
1,200
X = 1222
1,000
CV = 7 %
800
z'= 0,54
600
400
X = 390
200
0
0
2
4
6
8
10
12
14
16
18
20
22
24
Non-specific
-10
-9
-7
-8
log [Oligo] (M)
4,000
3,000
Oligonucleotide
Consensus
SP1
2,000
HNF1
1,000
+
+
+
+
+ - +++++++
Mutated
C
Consensus
Mutated
Non-Specific
+
Consensus
-6
HNF1
+
Mutated
IC50
value
2.3 nM
241,2 nM
Non-specific
81,1 nM
Consensus
121.6 nM
Mutated
N/A
Non-specific
N/A
0
-∞
-10
-9
-8
-7
-6
log [Oligo] (M)
The assay specificity was demonstrated for (A) Sp1 and (B) HNF1. Untagged wild-type
and non-specific DNA sequences were used as competitor for both assays. (C) A twolog difference in potency was observed between the consensus and non-specific
sequences for Sp1 with IC50 values of 2.3 and 241 nM, respectively. For HNF1, no
competitions occurred with non-specific oligonucleotides and a IC50 value of 122 nM
was generated with the specific DNA sequence. Results generated from the (D) EMSA
did not allow to demonstrate clearly the specificity of the HNF1 assay since partial
competition was observed between mutated and consensus DNA sequences compared
to a complete competition with the specific probe.
Summary
We have successfully demonstrated the application of
a homogenous AlphaLISA® assay to replace EMSA in
the monitoring of DNA-protein interaction from nuclear
extract samples.
•
1,000
Consenus
Mutated
0
Mutated HNF1
Nuclear extracts
0
12
A lysate titration experiment was then conducted for both (A) Sp1 and (B)
HNF1 detections using optimal assay conditions. As low as 1 µg/well of
non-stimulated Hep G2 nuclear extracts permit the generation of S/B
values of (A) 50.4 and (B) 2.6. However, wider assay window (6.4) for
HNF1 assay could be generated by increasing the amount of lysate per well
to 10 µg.
0
100,000
Consensus HNF1
Mutated
S/B= 6.4
log [Lysates] (g/well)
50,000
200,000
-∞
S/B= 2.6
-∞
150,000
Consensus
300,000
5,000
-5
A
Labeled HNF1
6,000
log [Lysates] (g/well)
-8
An antibody titration experiment was next performed using optimal
oligonucleotide concentration; (A) Sp1 [1 µg nuclear extract/well] and
(B) HNF1 [2 µg nuclear extract/well]. The greatest assay windows were
obtained with 10 and 1 nM of antibody for (A) Sp1 and (B) HNF1
detections, respectively.
HNF1
500,000
10
7,000
180 200
B
-∞
HNF1
-∞
120
Sp1
Antibody Titrations
7
60
Assay Sensitivity
3,000
400,000
B
0
A
4,000
-7
AlphaLISA Signal (counts)
•
Assay Buffer: 25 mM Hepes, 200 mM
NaCl, 0.1% Tween-20 (pH7.4)
Hep G2 nuclear extracts were prepared
according to standard protocols2 for Sp1
experiments or sourced commercially for
HNF1 experiments (Active Motif cat. no.
36011)
Biotinylated
and
untagged
oligonucleotides were synthesized and
annealed
to
generate
dsDNA
oligonucleotides per standard protocols
Anti-Sp1 Ab (sc-17824X) and anti-HNF1
Ab (sc-6547X) were from Santa Cruz
Protein A- (cat. no. AL101) and Protein G(cat. no. AL102) conjugated-AlphaLISA®
Acceptor beads were from PerkinElmer,
Inc.
Streptavidin (SA)-Donor beads (cat. no.
6760002) were from PerkinElmer, Inc.
White opaque 384-well Optiplates (cat.
no. 6007299) were from PerkinElmer, Inc.
TopSeal-A (cat. no. 6005185) were from
PerkinElmer, Inc.
Incubator set at 23oC
EnVision® reader was from PerkinElmer,
Inc.
Method
AlphaLISA Signal (counts)
•
0
Consensus
Mutated
6,000
To determine its optimal concentration, an oligonucleotide titration
curve was performed using fixed lysate concentration; (A) Sp1 [1
µg/well] and (B) HNF1 [2 µg/well]. Maximum response was observed
using (A) 10 nM and (B) 30 nM of oligonucleotides, with signal to
background ratio (S/B) value of 45.4 and 5.9, respectively.
Detection of binding between DNA and transcription factor (TF) is done
using Streptavidin-coated Donor beads that capture biotinylated DNA
sequence while the TF is recognized by a specific anti-TF antibody which
is captured by Protein A- or Protein G- conjugated AlphaLISA® Acceptor
beads. Following protein - DNA binding, beads are brought into close
proximity to produce an AlphaLISA signal.
4
100,000
9
Anti-transcription factor-conjugated
AlphaLISA Acceptor Bead
Materials
200,000
S/B=5.9
log [Biotinylated Oligos] (M)
3
Consensus
Mutated
S/B= 15.3
S/B= 6.2
7,500
AlphaLISA Signal (counts)
Sp1
-∞ -10
Streptavidin-coated
Alpha Donor Bead
300,000
AlphaLISA Signal (counts)
A
AlphaLISA Signal (counts)
Tramscription
factor
400,000
S/B= 7.4
A time course experiment was carried out on the detection step using
optimized assay conditions; (A) Sp1 [1 µg nuclear extract/well] and (B)
HNF1 [2 µg nuclear extract/well]. A final incubation of 60 minutes was
chosen for further experiment assessments even though S/B value could
be improved for Sp1 detection by incubating the reaction for a longer
period of time.
Biotinylated Oligonucleotide
Titrations
6
AlphaLISA Signal (counts)
Biotinylated
oligonucleotide
500,000
10,000
Detection incubation time (min)
S/B=45.4
Emission
615nm
S/B= 25.4
0
Assay Configuration
Excitation
680 nm
600,000
O/N
S/B= 6.4
Hep G2 nuclear extracts
Consensus
Mutated
Non-Specific
Competitior
probe
Biotin-Sp1 Consensus
O/N
S/B= 22.2
HNF1
D
Sp1
AlphaLISA Signal (counts)
Sp1 Consensus
B
Sp1
Assay Specificity
A
AlphaLISA Signal (counts)
Sequence (5’-3’)
ATTCGATCGGGGCGGGGCGAG
AlphaLISA Signal (counts)
2
Oligonucleotide
11
Detection Time Courses
A
AlphaLISA Signal (counts)
The interaction of proteins with DNA is central to the control of many cellular
processes including DNA replication, recombination and repair, transcription,
and viral assembly. The benchmark technique used to study protein:DNA
interactions is the electrophoretic mobility shift assay (EMSA). However,
standard EMSA suffers from being a radioactive assay and is suitable only for
low-throughput applications due to the requirement for a gel-based separation
step to identify bound probes. This work describes development of a higher
throughput non-radiometric assay to monitor the presence of specific DNAbinding proteins in nuclear extracts using a bead-based luminescent oxygen
channeling immunoassay. As proof of concept, we used Hep G2 nuclear extracts
to demonstrate binding of Sp1 and HNF1 transcription factors to tagged
oligonucleotides containing required cognate response elements. Using as little
as 1 µg of nuclear protein extract per well, with 10-30 nM of oligonucleotide, we
achieved a specific signal to background ratio of 50.4 and 2.6 for Sp1 and HNF1,
respectively. The HNF1 assay window could be increased more than two-fold
(S/B of 6.5) by increasing the amount of lysate. Using the Sp1-specific assay,
we measured a two-log difference in potency between the untagged wild-type
oligonucleotide and corresponding mutated probe in a competition format.
These results demonstrate that this novel non-radioactive DNA-binding assay
could represent a powerful alternative to EMSA when higher throughput is
desired.
8
Oligonucleotide Sequences
AlphaLISA Signa (counts)
5
Introduction
AlphaLISA Signal (counts)
1
Assay robustness was
then demonstrated by
generating Z’ value of
(A) 0.76 and (B) 0.54 for
Sp1 and HNF1
detections, respectively.
The assay was
performed using optimal
assay conditions in the
presence of (A) 1
µg/well and (B) 5
µg/well of Hep G2
nuclear extracts.
•This novel AlphaLISA detection assay represents a
major improvement over EMSA
•Non-Radiometric Assay
•Uses less DNA binding element
•Easier and faster to execute
•Greater throughput
•No need for running a gel
•Higher sensitivity
•The robustness of both assays was demonstrated by
generating Z’ value greater than 0.54.
•Competition assays have:
1. Confirmed the specificity of the detection.
2. Demonstrated the advantage of using Alpha by
using less binding element and at least two-fold
less nuclear extracts than required to study
interactions between TF and their respective DNA
sequence with methods commonly used.
CV = 11 %
References:
Well number
1PerkinElmer,
1
Vuori et al. FEBS J. (2009) ; 2 Schreiber et al. Nucleic Acids Res.. 17, 6419 (1989)
Inc., 940 Winter Street, Waltham, MA USA (800) 762-4000 or (+1) 203 925-4602 www.perkinelmer.com
2 Centre de Recherche, CHU Sainte-Justine, Montréal, Qc, Canada
3Département de Pédiatrie, Université de Montréal, Montréal, Qc, Canada